Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology)

Petar M. Seferovic*, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Cavusoglu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Seferovic, Pardeep S. Jhund, Giuseppe Dattilo, Jelena Celutkiene, Massimo Piepoli, Brenda MouraOvidiu Chioncel, Tuvia Ben Gal, Stephane Heymans, Tiny Jaarsma, Loreena Hill, Yuri Lopatin, Alexander R. Lyon, Piotr Ponikowski, Mitja Lainscak, Ewa Jankowska, Christian Mueller, Francesco Cosentino, Lars H. Lund, Gerasimos S. Filippatos, Frank Ruschitzka, Andrew J. S. Coats, Giuseppe M. C. Rosano

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

53 Citations (Web of Science)

Abstract

The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given:

center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended.

center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)1984-1986
Number of pages3
JournalEuropean journal of heart failure
Volume22
Issue number11
Early online date27 Oct 2020
DOIs
Publication statusPublished - Nov 2020

Keywords

  • Heart failure
  • Sodium&#8211
  • glucose co&#8208
  • transporter 2 inhibitors
  • Type 2 diabetes mellitus
  • Cardiovascular outcomes
  • Renal function

Cite this